tiprankstipranks
Innocan Pharma Advances Towards FDA Approval
Company Announcements

Innocan Pharma Advances Towards FDA Approval

Innocan Pharma Corporation (TSE:INNO) has released an update.

Stay Ahead of the Market:

Innocan Pharma Corporation has announced a significant advancement in the pharmaceutical industry by initiating the FDA approval process for its innovative LPT-CBD drug delivery technology, moving closer to achieving pharmaceutical-grade product status. The company has signed an agreement with the Hebrew University to meet FDA Chemistry Manufacturing Control (CMC) guidelines for its liposome CBD platform, marking a critical step towards clinical and marketing phases.

For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App